Method for measuring toxicity of human CSF
View Patent ↗The problem is to provide a method that can quickly and efficiently evaluate the toxicity of human cerebrospinal fluid (CSF) with small amounts of human CSF. The problem is solved by a method comprising administering human CSF into the cerebral ventricle of a rodent such as a mouse, and evaluating the cognitive function of the rodent by using a behavioral pharmacological technique.
1. A method for measuring a toxicity of human cerebrospinal fluid (CSF), comprising
administering human CSF into a cerebral ventricle of a rodent, and
evaluating a cognitive function of the rodent by using a behavioral technique,
wherein the evaluating is carried out at about one hour from the time of administering human CSF.
2. The method according to claim 1 , wherein the cognitive function evaluation is an evaluation of a short-term memory of the rodent.
3. The method according to claim 1 , wherein the behavioral technique is a Y-maze test.
4. The method according to claim 1 , wherein a dosage of the human CSF administered into the cerebral ventricle of the rodent is 5 μl or more.
5. The method according to claim 1 , wherein the rodent is a mouse.
6. The method according to claim 1 , wherein a dosage of the human CSF is 5 to 10 μL per rodent.
7. The method according to claim 6 , wherein the dosage is 10 μL per rodent.
8. The method according to claim 1 , wherein the human CSF is administered by injection.
9. A method for determining Alzheimer's disease, comprising
administering human CSF into a cerebral ventricle of a rodent, and
evaluating a cognitive function of the rodent by using a behavioral technique,
wherein the evaluating is carried out at about one hour from time of administering human CSF.
10. The method according to claim 9 , wherein the cognitive function evaluation is an evaluation of a short-term memory of the rodent.
11. The method according to claim 9 , wherein the behavioral technique is a Y-maze test.
12. The method according to claim 9 , wherein a dosage of the human CSF administered into the cerebral ventricle of the rodent is 5 μl or more.
13. The method according to claim 9 , comprising comparing the cognitive function of a rodent administered with a control into the cerebral ventricle and the cognitive function of the rodent administered with the human CSF into the cerebral ventricle.
14. The method according to claim 9 , wherein the rodent is a mouse.
15. The method according to claim 9 , wherein a dosage of the human CSF is 5 to 10 μL per rodent.
16. The method according to claim 15 , wherein the dosage is 10 μL per rodent.
17. The method according to claim 9 , wherein the human CSF is administered by injection.
18. A method for measuring the medicinal effect of an agent for treating Alzheimer's disease, comprising
(a) collecting human CSF from a subject after the administration of the agent;
(b) administering the human CSF collected in the step (a) into a cerebral ventricle of a rodent; and
(c) evaluating a cognitive function of the rodent administered with the human CSF collected after the administration of the agent,
wherein said cognitive function evaluation is performed using a behavioral technique, and
wherein the evaluating is carried out at about one hour from the time of administering human CSF.
19. The method according to claim 18 , wherein the cognitive function evaluation is an evaluation of the short-term memory of the rodent.
20. The method according to claim 18 , wherein the behavioral technique is a Y-maze test.
21. The method according to claim 18 , wherein the human CSF collected after the administration of the agent is administered into the cerebral ventricle of the rodent at a dose of 5 μl or more.
22. The method according to claim 18 , wherein the agent for treating Alzheimer's disease is an anti-amyloid β oligomer antibody.
23. The method according to claim 18 , wherein the agent for treating Alzheimer's disease is an antibody selected from the following (a) and (b):
(a) a monoclonal antibody in which complementarity determining region (hereinafter, “CDR”) 1, CDR2, and CDR3 of the heavy chain variable region (“VH”) of the antibody comprise the amino acid sequences represented by SEQ ID NOS: 3, 4, and 5, respectively, and CDR1, CDR2, and CDR3 of the light chain variable region (“VL”) of the antibody comprise the amino acid sequences represented by SEQ ID NOS: 6, 7, and 8, respectively; and
(b) a monoclonal antibody in which the VH of the antibody comprises the amino acid sequence represented by SEQ ID NO: 1, and the VL comprises the amino acid sequence represented by SEQ ID NO: 2.
24. The method according to claim 18 , wherein the rodent is a mouse.
25. The method according to claim 18 , wherein a dosage of the human CSF is 5 to 10 μL per rodent.
26. The method according to claim 25 , wherein the dosage is 10 μL per rodent.
27. The method according to claim 18 , wherein the human CSF is administered by injection.
28. A method for measuring the medicinal effect of an agent for treating Alzheimer's disease, comprising
(a) collecting human CSF from a subject starting or continuously undergoing administration of the agent before and after the administration of the agent;
(b) administering each of the human CSFs of before and after the administration of the agent collected in the step (a) into the cerebral ventricle of a rodent; and
(c) comparing a cognitive function of the rodent administered with the human CSF of before the administration of the agent and a cognitive function of the rodent administered with the human CSF of after the administration of the agent,
wherein said cognitive function is evaluated using a behavioral technique, and
wherein the evaluating is carried out at about one hour from the time of administering human CSF.
29. The method according to claim 28 , wherein a dosage of the human CSF is 5 to 10 μL per rodent.
30. The method according to claim 29 , wherein the dosage is 10 μL per rodent.
31. The method according to claim 28 , wherein the human CSF is administered by injection.
32. The method according to claim 28 , wherein the cognitive function evaluation is an evaluation of the short-term memory of the rodent.
33. The method according to claim 28 , wherein the behavioral technique is a Y-maze test.
34. The method according to claim 28 , wherein the human CSF collected after the administration of the agent is administered into the cerebral ventricle of the rodent at a dose of 5 μl or more.
35. The method according to claim 28 , wherein the agent for treating Alzheimer's disease is an anti-amyloid β oligomer antibody.
36. The method according to claim 28 , wherein the agent for treating Alzheimer's disease is an antibody selected from the following (a) and (b):
(a) a monoclonal antibody in which complementarity determining region (hereinafter, “CDR”) 1, CDR2, and CDR3 of the heavy chain variable region (“VH”) of the antibody comprise the amino acid sequences represented by SEQ ID NOS: 3, 4, and 5, respectively, and CDR1, CDR2, and CDR3 of the light chain variable region (“VL”) of the antibody comprise the amino acid sequences represented by SEQ ID NOS: 6, 7, and 8, respectively; and
(b) a monoclonal antibody in which the VH of the antibody comprises the amino acid sequence represented by SEQ ID NO: 1, and the VL comprises the amino acid sequence represented by SEQ ID NO: 2.
37. The method according to claim 28 , wherein the rodent is a mouse.